We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FDA Grants Fast-Track Designation to ZD6474 for Thyroid Cancer.
- Abstract
The article reports on the United States Food and Drug Administration's decision to grant fast-track designation for the investigation of ZD6474 (Zactima) in treating medullary thyroid carcinoma. The designation is intended to facilitate the development and expedite the review of investigational drugs being developed to treat serious or life-threatening conditions. ZD6474 is being studied as a multi-targeted compound, directed to the inhibition of key cell-signaling pathways involved in tumor growth and spread.
- Subjects
UNITED States; THYROID cancer; CANCER treatment; DRUG approval; UNITED States. Food &; Drug Administration
- Publication
Oncology (08909091), 2006, Vol 20, Issue 3, p264
- ISSN
0890-9091
- Publication type
Article